Gyre Therapeutics: Gyre Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024

Gyre Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported sales was USD 25.49 million compared to USD 32.04 million a year ago. Net income was USD 1.12 million compared to USD 3.98 million a year ago. Basic earnings per share from continuing operations was USD 0.01 compared to USD 0.06 a year ago. Diluted earnings per share from continuing operations was USD 0.01 compared to USD 0.05 a year ago. For the nine months, sales was USD 77.89 million compared to USD 86.3 million a year ago. Net income was USD 12.18 million compared to USD 8.07 million a year ago. Basic earnings per share from continuing operations was USD 0.14 compared to USD 0.13 a year ago. Diluted earnings per share from continuing operations was USD 0.05 compared to USD 0.1 a year ago.